Cyclophosphamide arrhythmogenicitytesting using human-induced pluripotent stem cell-derived cardiomyocytes

Cyclophosphamide (CP) is an anticancer drug, an alkylating agent. Cardiotoxicity of CP is associated with one of its metabolites, acrolein, and clinical cardiotoxicity manifestations are described for cases of taking CP in high doses. Nevertheless, modern arrhythmogenicity prediction assays in vitro...

Descripción completa

Detalles Bibliográficos
Autores principales: Podgurskaya, A. D., Slotvitsky, M. M., Tsvelaya, V. A., Frolova, S. R., Romanova, S. G., Balashov, V. A., Agladze, K. I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841168/
https://www.ncbi.nlm.nih.gov/pubmed/33504826
http://dx.doi.org/10.1038/s41598-020-79085-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841168/
https://www.ncbi.nlm.nih.gov/pubmed/33504826
http://dx.doi.org/10.1038/s41598-020-79085-5

Ejemplares similares